Chronic Kidney Disease News, Treatment Studies | CKD Clinical Research

Chronic Kidney Disease (CKD)


health worker talking to a man about his medication at home

Dapagliflozin Slows FSGS Progression

Dapagliflozin, an oral SGLT2 inhibitor, decreased the risk of progression of focal segmental glomerulosclerosis compared with placebo, a subgroup analysis of the DAPA-CKD trial showed.
Next post in Chronic Kidney Disease (CKD)